JNJ-7777120 was a drug being developed by Johnson & Johnson Pharmaceutical Research & Development which acts as a potent and selective antagonist at the histamine H4 receptor.[1] It has anti-inflammatory effects,[2] and has been demonstrated to be superior to traditional (H1) antihistamines in the treatment of pruritus (itching).[3] The drug was abandoned because of its short in vivo half-life and hypoadrenocorticism toxicity in rats and dogs, that prevented advancing it into clinical studies.[4]
Clinical data | |
---|---|
Other names | 1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
IUPHAR/BPS |
|
ChemSpider |
|
UNII |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.164.683 |
Chemical and physical data | |
Formula | C14H16ClN3O |
Molar mass | 277.75 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |